Radiotherapy improves progression-free survival in oligometastatic lung cancer
The SARON trial shows that adding consolidation radiotherapy to systemic therapy improves local control and progression-free survival but does not extend overall survival.
Adding consolidation radiotherapy to first-line systemic anticancer therapy significantly improves progression-free survival and reduces progression at sites of disease present at diagnosis for patients with synchronous oligometastatic non-small cell lung cancer (NSCLC). Median progression-free survival was 13.9 months with systemic therapy plus radiotherapy compared with 8.9 months with systemic therapy alone. This represents a 36% reduction in the hazard of progression or death.
The effect on local disease control was significant. Progression at sites of initial disease occurred in 13.0% of patients receiving consolidation radiotherapy versus 39.5% with systemic therapy alone. However, median overall survival was virtually identical at 31.0 months for the radiotherapy group and 28.0 months for the systemic therapy alone group.
The SARON trial was a multicenter randomized phase II study conducted across 22 centers in the United Kingdom. It enrolled 140 patients without targetable driver alterations who had one to five synchronous metastases involving up to three organs. Patients initially received approximately six to eight weeks of systemic anticancer therapy before randomization.
The study population included patients with a median age of 68 years, where 59.3% were men and 58.6% had adenocarcinoma. Enrollment ran from 2016 through 2023, and the control strategy was modified after immunotherapy entered routine first-line practice. Among participants, 40% received chemotherapy, 15% received immunotherapy, and 45% received combined chemoimmunotherapy.
The radiotherapy strategy was comprehensive. The primary lung tumor was treated with conventional radical radiotherapy or stereotactic ablative radiotherapy (SABR), while metastatic sites received SABR or stereotactic radiosurgery.
Key facts
- Median progression-free survival was 13.9 months with systemic therapy plus radiotherapy versus 8.9 months with systemic therapy alone.
- Progression at initial disease sites fell to 13.0% with consolidation radiotherapy compared to 39.5% with systemic therapy alone.
- Median overall survival was 31.0 months with radiotherapy versus 28.0 months with systemic therapy alone.
Three perspectives
Neutral
The SARON trial demonstrates that while consolidation radiotherapy improves local disease control and progression-free survival, it does not translate into longer overall survival.
Positive
Adding consolidation radiotherapy to first-line systemic therapy significantly improved progression-free survival and substantially reduced progression at existing disease sites.
Negative
The improvement in progression-free survival did not result in a longer overall survival for patients.
Your week in news, every Wednesday
The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.